1/54
Looks like no tags are added yet.
Insulin
-Released by beta-cells in islets of Langerhans in response to increased blood glucose
• Basal amount secreted throughout the day (basal secretion)
• Increases in insulin secretion in response to food intake (prandial secretion)
• Promotes uptake of glucose into cells for use as energy or storage
Glucagon
Released by alpha-cells in the islets of Langerhans in response to decreased blood glucose
Amylin
Peptide hormone co-secreted by pancreatic beta cells with insulin
Prevent or delay the progression of long-term micro- and macrovascular complications
primary goal of therapy for diabetes mellitus
1%
A ______% reduction in A1C results in risk reduction of: 37% for microvascular complications, 14% for myocardial infarction, and 21% for death.
• Alleviate symptoms of hyperglycemia
• Minimize hypoglycemia and other adverse effects
• Minimize treatment burden
• Maintain quality of life
secondary goals of therapy for diabetes mellitus
7%
Goal:
Hemoglobin A1C < _______%
80-130
Goal:
Pre-prandial plasma glucose: ________ mg/dL
180
Goal;
Peak post-prandial plasma glucose:
• Corticosteroids
• Loop diuretics
• Thiazide diuretics
• Phenytoin
• b-blockers
medications that increase plasma glucose
• Other antihyperglycemic medications
• Alcohol
• Salicylates
• Fluoroquinolones
• Antidepressants
medications that increase hypoglycemia
Beta-Blockers
drugs that increase plasma glucose, and therefore mask the symptoms of hypoglycemia
Somatostatin Analogues
-inhibit insulin and glucagon secretion
Rapid-acting
Regular (short-acting)
Intermediate-acting
Long-acting
Ultra Long-Acting
what are the types of insulin?
Oral Insulin
What formulations cannot be utilized due to poor absorption and enzymatic degradation within the gastrointestinal tract?
• Hypoglycemia
• Weight gain
• Lipodystrophy
• Hypokalemia
Adverse reactions of insulin
Akt
-regulates the activity of GLUT4 and PKC which plays a critical role in metabolism and catabolism
• PO Glucose
-Orange juice, candy, etc.
-Recheck blood sugar
-Repeat if needed
treatment for a hypoglycemic pt that is conscious
• IV Dextrose
OR
• IM Glucagon (1mg)
treatment for a hypoglycemic pt that is unconscious
2.5 minutes
ultra rapid acting insulin reaches the blood in ________________
Subcutaneous Injection
what is the most common route for insulin administration
Basal Insulin
• Controls blood glucose in the fasting state
• Mimics basal or baseline pancreatic insulin secretion
• Insulin given to control hepatic glucose production in the absence of food
• Dose often reduced (~50%) when patients NPO
• Approximately 50% of daily insulin requirements
Intermediate or long-acting
which insulin is used to
provide basal insulin coverage, with delayed
absorption and a longer duration of activity (basal insulin)?
Bolus Insulin
• Controls blood glucose spikes surrounding mealtimes
• Mimics postprandial insulin pancreatic secretion when blood glucose rises after food ingestion
• Insulin given to limits hyperglycemia after meals
• Approximately 50% of daily insulin requirements
• 10-20% of daily requirement at each meal
Rapid or Short Acting
which insulin is used for immediate coverage for a rapid rise in blood glucose, with a sharp peak and shorter duration of activity (bolus)?
Prandial
scheduled insulin administered prior to meals, to cover planned meal intake of carbohydrates
Correctional (supplemental)
corrects hyperglycemia detected before or between meals based on BG monitoring
Insulin aspart (Fiasp)
-ultra rapid-acting insulin
-contains form of vitamin B3 (niacinamide), which increases the speed of initial insulin absorption, and an amino acid to aid stability.
Insulin aspart (Fiasp)
• Onset of action: 2-15 min
• Increased solubility --> rapid dissociation
• Duration of action: 4-5 hours
-improve glycemic control
• Administration: at beginning or within 20 minutes of a minutes of a meal
• Mealtime insulin replacement
• Carbohydrate intake
considerations for dosing of ultra-rapid and rapid Insulin
Insulin humanis-inhaled (Afrezza)
-ultra-rapid acting insulin
• Onset of action: 5-12 min
• Duration of action: 1.5-4.5 hours
Insulin humanis-inhaled (Afrezza)
• Diabetes mellitus, types 1 and 2, treatment:
• BBW: Acute bronchospasm in chronic lung disease = Contraindicated
• Rapid-acting for inhalation before meals
• Inferior to injection comparing A1C
• Lower hypoglycemia risk
-Insulin lispro (Humalog)
-Insulin aspart (NovoLog)
-Insulin glulisine (Apidra)
Rapid-Acting Insulins
-Insulin aspart (Fiasp)
-Insulin humanis-inhaled (Afrezza)
Ultra-Rapid Insulins
Rapid-Acting Insulin
• Modification of 1-2 amino acids on B chain
• Onset of action: 10-20 min
• Duration of action: 3-6 hours
-Control of post-prandial glucose levels
• Administration: 10-15 minutes before meals
• Helps to reduce hypoglycemia risk
Regular Insulin (short-acting)
-recombinant human protein
• Onset of action: 30 min
• Duration of action: 5- 8 hours
-Control of glucose levels
• Administration: 30 minutes before meals
U-500 (Unique Intermediate Acting Insulin)
-concentrated regular insulin with prolonged duration
-onset: 15-30 min
-basal and bolus
• Eliminates need for separate basal and bolus agents
• Dosed 2-3 times a day
• Often considered for patients with high insulin requirements & resistance by diabetes specialist
• High risk medication
Neutral protamine Hagedorn (NPH)
-Intermediate-Acting Insulin
-Complexed insulin-zinc precipitated with protamine for decrease solubility and delay absorption
• Onset of action: 1-2 hours
• Duration of action: 16-24 hours
-Basal control of glucose levels
-Administration: Two times per day in regard to meals
AM and PM
when is NPH administered?
-Insulin glargine
-Insulin detemir
-Insulin glargine
Long-Acting Insulins
Insulin detemir
long acting insulin that has an addition of myrisitc acid to the A chain
-makes it a stable precipitate
Long-Acting Insulins
Role in therapy:
• Basal control of glucose levels
• Have higher hypoglycemia risk
• Generally dosed 1 time per day
Insulin degludec
-Ultra Long-Acting Insulin
• Recombinant, stabilized form with large particle size
• Onset of action: 30-90 min
• Duration of action: 42 hours
Insulin degludec
-Basal control of glucose levels
• Administration: One time per day
• Have higher hypoglycemia risk
Insulin glargine
Which long acting insulin develops over 6 hours and lasts for > 24 hours
Dosing pens
-type of insulin preparation
• Designed for ease of dosing
• Easy to transport
• No refrigeration required
0.4-0.5
Recommended starting daily dose of insulin for T1DM: _____________units/kg/day
Neutral protamine Hagedorn (NPH)
______________ regimens = Higher risk for hypoglycemia
Continuous subcutaneous insulin infusion (CSII)
-Intensive glycemic control for adherent patients
-pt must be motivated, adherent, and competent to use the device
-typically utilizes rapid-acting insulin
Insulin to carbohydrate ratio (I:C)
• Estimated units of insulin required per
carbohydrate amount
• Used to determine pre-meal dosing
• Estimated: 550 / TDD
Insulin sensitivity factor (ISF)
• Estimated glucose lowering expected from 1 unit of insulin
• Used for "correctional insulin" calculation, also sometimes called CF (correction factor)
• Estimated: 1650 / TDD
Pramlintide
• MOA: Amylin analog
-adjunctive therapy for T1DM
• Delays gastric emptying, decreases glucagon secretion, increases satiety
• Decreases A1C
• Lowers insulin doses
Teplizumab
Drug That Can Delay Onset of Type 1 Diabetes
Teplizumab
-immunomodulatory monoclonal antibody works by binding to CD3 to delay the onset of stage 3 T1D
-with their CD3 activation
and function
• Restoration of intravascular volume
• Electrolyte replacement
• Insulin given by continuous IV infusion (regular insulin used)
• Generally, avoid administration of bicarbonate
treatment for Diabetic Ketoacidosis (DKA)